Sign inCreate account

Report workspace tools

NCT02055157COMPLETEDanonymous

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Sponsor

Source record

BioMarin Pharmaceutical

Phase

Source record

PHASE2

Modality

AI-normalized

small molecule

Target

AI-normalized

BMN 111

Indication / condition

AI-normalized

Achondroplasia

Intervention

Source record

BMN 111

Source & freshness

Source record

NCT ID

NCT02055157

Original source

ClinicalTrials.gov

Source last updated

Jan 15, 2021

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02055157

Title

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Sponsor

BioMarin Pharmaceutical

Status

COMPLETED

Phase

PHASE2

Condition raw

Achondroplasia

Condition normalized

Achondroplasia

Modality raw

small molecule

Modality normalized

small molecule

Target raw

BMN 111

Target normalized

BMN 111

Interventions

BMN 111

Public preview

Source record

This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 2, Open-label, Sequential Cohort Dose-escalation Study of BMN 111 in Children With Achondroplasia

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02055157

Status

COMPLETED

Phase

PHASE2

Sponsor

BioMarin Pharmaceutical

Executive brief

Investment-Ready Snapshot

This is a Phase 2, open-label, sequential cohort dose-escalation study of BMN 111 in children with achondroplasia. The primary objective is to assess the safety and tolerability of daily BMN 111 administered to children with achondroplasia.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedJan 15, 2021
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02055157

Indication

Achondroplasia

Modality

small molecule

Target

BMN 111

Intervention

BMN 111

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.